ATE492281T1 - Verwendung von glucocorticoid-rezeptor- spezifischen antagonisten zur behandlung von delirium - Google Patents

Verwendung von glucocorticoid-rezeptor- spezifischen antagonisten zur behandlung von delirium

Info

Publication number: ATE492281T1
Authority: AT; Austria
Prior art keywords: glucocorticoid receptor; receptor antagonist; specific antagonists; delirium; methods
Prior art date: 2001-05-04

Application number

AT02731689T

Other languages

English (en)

Inventor

Joseph Belanoff

Original Assignee

Corcept Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-04

Filing date

2002-05-06

Publication date

2011-01-15

2002-05-06 Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc

2011-01-15 Application granted granted Critical

2011-01-15 Publication of ATE492281T1 publication Critical patent/ATE492281T1/de

Links

206010012218 Delirium Diseases 0.000 title abstract 3
239000005557 antagonist Substances 0.000 title 1
239000003862 glucocorticoid Substances 0.000 title 1
229940126013 glucocorticoid receptor antagonist Drugs 0.000 abstract 3
239000003850 glucocorticoid receptor antagonist Substances 0.000 abstract 3
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
239000003795 chemical substances by application Substances 0.000 abstract 1
229960000890 hydrocortisone Drugs 0.000 abstract 1
239000000463 material Substances 0.000 abstract 1
VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 abstract 1
229960003248 mifepristone Drugs 0.000 abstract 1
230000003389 potentiating effect Effects 0.000 abstract 1
102000005962 receptors Human genes 0.000 abstract 1
108020003175 receptors Proteins 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Oncology (AREA)
Endocrinology (AREA)
Communicable Diseases (AREA)
Vascular Medicine (AREA)
Anesthesiology (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Steroid Compounds (AREA)

AT02731689T 2001-05-04 2002-05-06 Verwendung von glucocorticoid-rezeptor- spezifischen antagonisten zur behandlung von delirium ATE492281T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US28861901P	2001-05-04	2001-05-04
US13780002A	2002-05-01	2002-05-01
PCT/US2002/014318 WO2002096433A1 (en)	2001-05-04	2002-05-06	Methods for treating delirium using glucocorticoid receptor-specific antagonists

Publications (1)

Publication Number	Publication Date
ATE492281T1 true ATE492281T1 (de)	2011-01-15

Family

ID=26835589

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02731689T ATE492281T1 (de)	2001-05-04	2002-05-06	Verwendung von glucocorticoid-rezeptor- spezifischen antagonisten zur behandlung von delirium

Country Status (11)

Country	Link
EP (1)	EP1390037B1 (de)
JP (2)	JP2005512949A (de)
CN (1)	CN1527713A (de)
AT (1)	ATE492281T1 (de)
AU (1)	AU2002303652B2 (de)
CA (1)	CA2446506C (de)
DE (1)	DE60238671D1 (de)
IL (2)	IL158744A0 (de)
NO (1)	NO334736B1 (de)
NZ (1)	NZ529456A (de)
WO (1)	WO2002096433A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN100531738C (zh) *	2001-10-26	2009-08-26	欧加农股份有限公司	(11β,17β)-11-(1,3-苯并间二氧杂环戊烯-5-基)-17-羟基-17-(1-丙炔基)雌-4,9-二烯-3-酮在治疗重性抑郁症中的应用
JP6053802B2 (ja) *	2011-10-07	2016-12-27	コーニンクレッカフィリップスエヌヴェＫｏｎｉｎｋｌｉｊｋｅＰｈｉｌｉｐｓＮ．Ｖ．	患者を監視し、患者のせん妄を検出する監視システム
CN116168840B (zh) *	2023-04-23	2023-12-22	北京大学人民医院	一种预测术后谵妄发生风险的方法、设备及系统

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3464012B2 (ja) *	1993-04-05	2003-11-05	旭化成株式会社	精神症候治療剤
IL110309A0 (en) *	1993-07-15	1994-10-21	Univ Kentucky Res Found	A method of protecting against neuron loss
AU747956B2 (en) *	1997-10-06	2002-05-30	Board Of Trustees Of The Leland Stanford Junior University	Methods for treating psychosis associated with glucocorticoid related dysfunction
CA2328411C (en) *	1998-05-15	2008-12-16	Alan F. Schatzberg	Glucocorticoid receptor antagonists for the treatment of dementia
JP2004525135A (ja) *	2001-03-23	2004-08-19	コーセプトセラピューティクス，インコーポレイテッド	糖質コルチコイドレセプター特異的アンタゴニストを使用するストレス障害を処置するための方法

2002
- 2002-05-06 AT AT02731689T patent/ATE492281T1/de active
- 2002-05-06 WO PCT/US2002/014318 patent/WO2002096433A1/en not_active Ceased
- 2002-05-06 AU AU2002303652A patent/AU2002303652B2/en not_active Ceased
- 2002-05-06 DE DE60238671T patent/DE60238671D1/de not_active Expired - Lifetime
- 2002-05-06 CN CNA028126726A patent/CN1527713A/zh active Pending
- 2002-05-06 CA CA2446506A patent/CA2446506C/en not_active Expired - Fee Related
- 2002-05-06 EP EP02731689A patent/EP1390037B1/de not_active Expired - Lifetime
- 2002-05-06 IL IL15874402A patent/IL158744A0/xx unknown
- 2002-05-06 NZ NZ529456A patent/NZ529456A/en not_active IP Right Cessation
- 2002-05-06 JP JP2002592943A patent/JP2005512949A/ja active Pending
2003
- 2003-11-04 IL IL158744A patent/IL158744A/en not_active IP Right Cessation
- 2003-11-04 NO NO20034916A patent/NO334736B1/no not_active IP Right Cessation
2008
- 2008-12-09 JP JP2008313766A patent/JP2009102346A/ja active Pending

Also Published As

Publication number	Publication date
AU2002303652B2 (en)	2006-08-31
EP1390037B1 (de)	2010-12-22
JP2009102346A (ja)	2009-05-14
WO2002096433A9 (en)	2003-02-06
IL158744A (en)	2011-11-30
IL158744A0 (en)	2004-05-12
HK1059036A1 (en)	2004-06-18
NO20034916L (no)	2004-01-05
WO2002096433A1 (en)	2002-12-05
NO20034916D0 (no)	2003-11-04
NZ529456A (en)	2005-10-28
NO334736B1 (no)	2014-05-19
DE60238671D1 (de)	2011-02-03
EP1390037A4 (de)	2005-03-30
EP1390037A1 (de)	2004-02-25
JP2005512949A (ja)	2005-05-12
CA2446506C (en)	2012-04-10
CN1527713A (zh)	2004-09-08
CA2446506A1 (en)	2002-12-05

Legal Events

Date

Code

Title

Description

2011-06-15

UEP

Publication of translation of european patent specification

Ref document number: 1390037

Country of ref document: EP

Publication	Publication Date	Title
DE69833502D1 (de)	2006-04-20	Glucocorticoid receptor antagonisten zur behandlung von demenz
ATE406166T1 (de)	2008-09-15	Verfahren zur prävention von gewichtszunahme infolge von antipsychotika
DE69835225D1 (de)	2006-08-24	Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen
WO2002076390A3 (en)	2003-05-22	Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
EP1156792A4 (de)	2004-12-08	Methoden und zusammenstellungen zur behandlung des reizdarmsyndroms unter verwendung von niedrigdosierten antagonisten des opioidrezeptors
WO2004058717A8 (en)	2004-08-19	Isoquinolinone derivatives and their use as therapeutic agents
ATE507210T1 (de)	2011-05-15	Chinazolinon modulatoren von nukleinrezeptoren
ATE450508T1 (de)	2009-12-15	Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren
DE60228073D1 (de)	2008-09-18	Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen
DE60229411D1 (de)	2008-11-27	Verfahren zur hemmung der verschlechterung der kognitiven leistungsfähigkeit bei erwachsenen mit down-syndrom
HK1047050A1 (zh)	2003-02-07	治疗轻度智力机能缺陷的方法
ATE529116T1 (de)	2011-11-15	Verfahren zur verstärkung des therapeutischen ansprechens auf elektrokonvulsive therapie (ect)
MX2007004306A (es)	2007-06-07	Compuestos biciclicos como antagonistas del receptor de la hormona concentradora de melanina selectivos para el tratamiento de la obesidad y trastornos relacionados.
WO2004069202A3 (en)	2005-01-06	Antiglucocorticoids for the treatment of postpartum psychosis
ATE317268T1 (de)	2006-02-15	Verwendung eines h1-antagonisten und von rimexolon als sicheres steroid zur behandlung von rhinitis
DE60238671D1 (de)	2011-02-03	Verwendung von glucocorticoid-rezeptor-spezifischen antagonisten zur behandlung von delirium
ATE393766T1 (de)	2008-05-15	Biaryltetrahydroisochinolin-piperidine als selektive mch-rezeptor-antagonisten zur behandlung von adipositas und verwandten erkrankungen
DE60006948D1 (de)	2004-01-15	Antagonismus des estrogen-rezeptors-beta und knochenkrankheiten
WO2002020526A3 (en)	2002-05-30	Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents
ATE396996T1 (de)	2008-06-15	Selektive d1/d5 rezeptorantagonisten zur behandlung von fettleibigkeit und von zns störungen